Genetic Mutations and Family History
705 articles
Damage as a Way to Repair Pancreatic Cancer
Dr. Talia Golan takes a closer look at the damage caused by the BRCA1/2 mutations to find a way to treat pancreatic cancer.
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
Understanding Family History Makes a Difference in Treatment Options
Elizabeth Pršić describes her mother Andrea’s pancreatic cancer treatment. Andrea has the BRCA2 mutation, which helps determine the plan.
Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligible to try a new drug.
Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
Using the Energy Around Me to Help Me Heal
Judith Glaser’s genetic mutation influenced her chemotherapy and radiation treatments, supported by the healing energy of friends.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
A Second Opinion Makes the Difference
Irma Infante refused to give up after a stage IV pancreatic cancer diagnosis. She went for a second opinion and better treatment options.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
The Value of Molecular Profiling and Genetic Testing
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random.
Early Diagnosis Is Important
Jami Curry knew her family history included breast and pancreatic cancer, so she was alert to any health changes.
Tailoring My Treatment to My Tumor Genetics
After diagnosis with pancreatic cancer, Sharon Simone had her tumor analyzed. The report on her tumor genetics determined her treatment.